SC 13G: Immatics N.V.

Ticker: IMTX · Form: SC 13G · Filed: Nov 14, 2024 · CIK: 1809196

Sentiment: neutral

Topics: sc-13g

AI Summary

SC 13G filing by Immatics N.V..

Risk Assessment

Risk Level: low

Filing Stats: 1,290 words · 5 min read · ~4 pages · Grade level 8.1 · Accepted 2024-11-14 06:32:45

Filing Documents

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is Immatics N.V. (the " Company ").

(b)

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Company's principal executive offices are located at Paul-Ehrlich-Straße 15, 72076 Tübingen, Federal Republic of Germany.

(a)

Item 2(a). NAME OF PERSON FILING: This statement is filed by: (i) RTW Investments, LP (" RTW Investments "), a Delaware limited partnership, and the investment adviser to certain funds (the " RTW Funds "), with respect to the Shares (as defined in

(d) below) directly held by the RTW Funds; and

Item 2(d) below) directly held by the RTW Funds; and (ii) Roderick Wong, M.D. (" Dr. Wong "), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. The foregoing persons are hereinafter sometimes collectively referred to as the " Reporting Persons ." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

(b)

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the business office of each of the Reporting Persons is 40 10 th Avenue, Floor 7, New York, New York 10014.

(c)

Item 2(c). CITIZENSHIP: RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.

(d)

Item 2(d). TITLE OF CLASS OF SECURITIES: Ordinary Shares, nominal value 0.01 per share (the " Shares "). CUSIP No. N44445109 13G Pages 5 of 7 Pages

(e)

Item 2(e). CUSIP NUMBER: N44445109 Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) ¨ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) x Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) ¨ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth herein are calculated based upon 103,105,906 Shares outstanding as of June 30, 2024, as reported in Exhibit 99.1 to the Company's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on August 13, 2024. CUSIP No. N44445109 13G Pages 6 of 7 Pages Item 5. Not applicable. Item 6.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct. DATED: November 14, 2024 RTW INVESTMENTS, LP By: /s/ Roderick Wong, M.D. Name: Roderick Wong, M.D. Title: Managing Partner /s/ Roderick Wong, M.D. RODERICK WONG, M.D.

View Full Filing

View this SC 13G filing on SEC EDGAR

View on Read The Filing